Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients

Oral Oncol. 2020 Mar:102:104509. doi: 10.1016/j.oraloncology.2019.104509. Epub 2019 Dec 12.

¹ Department of Oral Surgery, Sapporo Medical University, School of Medicine, Japan. Electronic address: ogi@sapmed.ac.jp.
² Department of Oral Surgery, Sapporo Medical University, School of Medicine, Japan.
³ Department of Radiology, Sapporo Medical University, School of Medicine, Japan.
⁴ Department of Medical Oncology, Sapporo Kyoritsu Gorinbashi Hospital, Japan.
⁵ Department of Medical Oncology, Sapporo Medical University, School of Medicine, Japan.
⁶ Medical Genome Science, Research Institute for Frontier Medicine, Sapporo Medical University, School of Medicine, Sapporo, Japan.
⁷ Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University, Sapporo, Japan.
⁸ Department of Oral Surgery, Sapporo Medical University, School of Medicine, Japan; Department of Oral and Maxillo-Facial Surgery, Toya Kyokai Hospital, Japan.

No abstract available

Keywords: Immune check point inhibitor; Oral cancer; Somatic mutations and copy number variations.

Publication types